Prediction of drug absorption: different modeling approaches from discovery to clinical development
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Drug absorption modeling is a task that requires different tools depending on the drug development stage. Scientific progress and increased computer power have initiated a veritable revolution of modeling and simulation. Technical developments have enabled a high model complexity that was unthinkable only a couple of years ago. Today, model simulations can be used to guide experimental planning and, in some cases, the extent of work can even be reduced. There are several success stories of pharmaceutical modeling and the prediction of a drug's absorption, distribution, metabolism, and excretion (ADME) properties has certainly been of particular interest. Considering the advances in this area, the question can be raised, how close is the pharmaceutical industry to a 'prediction paradise' [1] . How wide are the gaps with respect to good predictions? The present editorial addresses this question, but with an exclusive focus on drug absorption modeling. The opportunities and limitations of drug absorption prediction are often viewed differently depending on the scientist asked. A discovery researcher, for example, tries to anticipate the extent of absorption based on the chemical structure alone. Approaches range from basic molecular property rules [2] to more recent approaches using advanced statistical procedures [3] [4] [5] [6] [7] . However, even more challenging than intestinal absorption is the prediction of oral bioavailability. In the latter case, additional drug clearance may lead to an increased scattering to the experimental data. Starting with the chemical structure, there are interesting approaches to quantitative structure-bioavailability relationship [8, 9] . However, it is fair to raise the question of whether bioavailability can be well predicted at all, based on the chemical structure [10, 11] . The answer to this question must, in any case, consider the various needs of prediction accuracy. In discovery, the goal is to select a promising drug candidate, thus the prediction of an absorption and bioavailability potential seems to be sufficient. However, once a drug candidate is chosen, more accurate and versatile tools are required.
It must be kept in mind that oral bioavailability is influenced by a series of physiological factors. In particular, the formulation often plays a dominating role. These important factors cannot be inferred from the chemical structure alone. Furthermore, there are relevant physico-chemical drug properties apart from the structure. Thus, particle size distribution and the polymorphic form often impact drug dissolution and absorption. The poorly soluble drugs of the biopharmaceutical classes II or IV are [12] , which was further refined in an advanced version (ACAT) [13] and this model is used in the commercial program GastroPlus™ (Simulations Plus). A competitor program of whole-body physiologically based modeling is PK-SIM ® (Bayer Technology Services). The latter model assumes a continuous tube for the gastrointestinal tract and validation was performed in different species [14] [15] [16] .
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Physiologically based models offer a variety of simulation opportunities but they are also demanding with respect to the high number of input parameters. A preclinical scientist has to cope with the lack of knowledge and incertainty concerning a new drug. Before the drug is first tested in humans, there are many unknowns, meaning that only rough estimates or even default values must be used for initial simulations. However, such early predictions are still of great interest, since the absolute values are often of lesser importance compared with their change with altered input variables. Thus, clinically relevant doses can be checked in silico with respect to their potential to result in erratic drug absorption. Similarly, the effect of physical parameters, such as particle size, on drug absorption can also be simulated. The results can highlight which parameters might be sensitive to reduced drug absorption. Accordingly, it is possible to anticipate potential development risks, and a parameter sensitivity ana lysis has been applied successfully to define the formulation strategy for clinical development [17] [18] .
Despite successful applications, the remaining gaps towards a reliable prediction of oral drug absorption should not be underestimated. Such gaps mainly arise from incomplete knowledge of the absorption behavior of drugs, dependent on formulation and food effects. A better understanding of these factors and their interactions is required. Therefore, additional research must proceed before more refined models can be proposed. Such research could be focused on in vitro tests, whose relevance to drug absorption must be demonstrated by corresponding in vivo experiments. An interesting area of such in vitro tests concerns the dissolution and solubility of drugs in physiological media. It is crucial to anticipate the solubilization of poorly soluble drugs in simulated intestinal media. These biorelevant media were introduced to better estimate the in vivo solubilization of a drug [19] [20] [21] . Current research aims to improve existing recipes and new media were proposed recently for the early, mid and late stages of a fed condition [22] . These in vitro tests are essential when predicting the absorption of lipophilic drugs to avoid considerable errors due to imprecise solubility estimates.
Aside from a better understanding of the effects in the fasted and fed states, modeling the different formulation approaches, which have the potential to improve the bioavailability of poorly soluble compounds is also of great interest. Among those relevant formulation types are solid dispersions or oral lipid-based drug delivery systems. The latter systems are particularly complex and can influence drug absorption on various mechanistic levels [23] . Lipid systems must be investigated by means of compendial dissolution equipment [24] , as well as by using new in vitro tests [25] [26] . The obtained data can then be used to better model the potential of these formulations to enhance absorption and bioavailability of biopharmaceutical classification system II and IV compounds. Improved in vitro tests enable more accurate input data for drug absorption modeling. It is even conceivable to design new tailor-made in vitro tests for a given, physiologically based drug absorption model.
Having good in vitro tests in the preclinical phase is naturally also important to anticipate the effects of presystemic clearance. Once a drug is tested in humans, the quality of the preclinical prediction becomes apparent. Accordingly, the Phase 1 clinical studies provide the most important reality check for a drug absorption model, but it is not the end of the model's evolution. The initial clinical data are used to update the assumed pharmacokinetic parameters in the physiologically based models. Having a lower degree of uncertainty, it is now possible to address questions that might appear far too ambitious during the preclinical phase. The models allow assessment of the effects of different ethnic populations, physiological conditions or drug-drug interactions in silico. An extension to the previously mentioned parameter sensitivity study is possible, if physiologically based modeling is performed in the framework of a statistical design. This new approach can be used to generate a so-called drug absorption design space [27] . A multidimensional response area of drug absorption can be calculated as a function of the relevant input variables. Such a response surface can be very helpful in the market formulation development and can generally feedback into the clinical drug development. Even following drug approval, such models can be of great interest for generic companies in the preparation of a bioequivalence study.
In summary, it should be emphasized that, parallel to drug development, there is also an evolution of absorption models and predictions are becoming more reliable with decreasing uncertainty. Physiologically based models enable model evolution and improved predictions also lead to new opportunities. Even today, the models' predictions can aid in anticipating drug development risks and the simulations can guide the clinical formulation development or the design of clinical studies. Thus, we are certainly not yet in a prediction paradise, while immense progress has been made in recent years. 
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